drug · protein
bremelanotide acetate
Marketedupdated 3mo agoby $PTNT PALATIN TECHNOLOGIES INC🔗 ChEMBL
Approvedcommunity read0 votes
Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for mental or behavioural disorder and sexual dysfunction and 1 investigational indication.
indications
investigational
Obesity
targets
Melanocortin receptor 4
all catalysts(0)
nothing on the calendar yet
Trials studying bremelanotide acetate
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 5, 2033
~7.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Apr 29, 2041method-of-use (U-3539)US 11590209
- Nov 5, 2033method-of-use (U-2568)US 10286034
- Nov 5, 2033method-of-use (U-2568)US 9352013
- Nov 5, 2033method-of-use (U-2568)US 9700592
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that